Pharmaceutical Executive May 26, 2022
As rare disease drug development increases, Javier Szwarcberg, MD, MPH, CEO of Spruce Biosciences, discusses the challenges in this space, and how his background is helping him find solutions for patients, specifically with endocrine disorders.
Pharm Exec: What is your experience in rare disease?
Szwarcberg: For the majority of my professional pharmaceutical career and forming years as a physician, I have chosen to focus on rare diseases. This began early in my career during my fellowship in Pulmonary and Critical Care at Mount Sinai Health System, where I worked closely with my mentor Dr. Alvin Teirstein researching sarcoidosis, a rare disease characterized by the growth of tiny collections of inflammatory cells (granulomas) throughout the body. Following my fellowship, I continued...
Today's Sponsors
Today's Sponsor